R-Rt92-logo-rbg0.png
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
20 nov. 2024 08h00 HE | Route 92 Medical, Inc.
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
20 nov. 2024 07h55 HE | ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
R-Rt92-logo-rbg0.png
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
23 sept. 2024 09h00 HE | Route 92 Medical, Inc.
Route 92 Medical announces $50 million series F extension equity financing to support its commercial expansion.
Company logo.png
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President
11 sept. 2024 07h00 HE | Pharmazz, Inc.
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President.
Company logo.png
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
21 août 2024 07h00 HE | Pharmazz, Inc.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
Bioxodes annonce la
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
21 août 2024 02h30 HE | Bioxodes
 Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients  L’analyse des...
Bioxodes reports pos
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
21 août 2024 02h30 HE | Bioxodes
 Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients  Interim data from 16 patients scheduled around the end of 2024 ...
Bioxodes franchit un
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
27 juin 2024 02h30 HE | Bioxodes
 Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
27 juin 2024 02h30 HE | Bioxodes
 First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
image (5).png
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI
25 juin 2024 09h00 HE | Qure.ai Technologies Limited
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI.